1995-1999 Doctor of Medicine/Internal Medicine: Kyoto University, Japan
1990-1995 Master of Medical Microbiology: Harbin Medical University, China
1984-1990 Bachelor of Medicine: Harbin Medical University, China
2010 Shanghai Outstanding Academic Leader
2011 Shanghai Leading Medical Talent
2009-present - Fudan University, Institute of Biomedical Sciences - Researcher
2009-present - Fudan University, Shanghai Public Health Clinical Center - Joint Professor
2010-2019 - Shanghai Institute of Emerging and Re-emerging Infectious Diseases - Founding Director
2019-2021 - Zhongshan Hospital South Campus Biotherapy Center - Executive Director
2021-present - Fudan University Affiliated Zhongshan Hospital - Joint Professor
2002-2007, 2009 - China CDC AIDS Prevention and Control Center - Associate Researcher/Researcher
2000-2002 - New York University School of Medicine - Postdoctoral Fellow
1999-2000 - Tohoku University School of Medicine, Japan - Assistant Professor
2011: Third Prize of Shanghai Medical Science and Technology Award for New Technology for Predicting Mucosal Potential Immune Damage
2019: Shanghai Women's Contribution to Nation Building Award
Research
Dissecting immune protective mechanisms against viral infection, particularly mucosal infection Developing immunopreventive or immunotherapeutic approaches against viral infection and implementing translational research Developing immunotherapeutic approaches against solid tumors and implementing translational research
Efficacy and Safety of Novel Multifunctional M10 CAR-T Cells in HIV-1-Infected Patients: A Phase I, Multicenter, Single-Arm, Open-Label Study, Yunyu Mao, Qibin Liao, Youwei Zhu, Mingyuan Bi, Jun Zou, Nairong Zheng, Lingyan Zhu, Chen Zhao, Qing Liu, Li Liu, Jun Chen, Ling Gu, Zhuoqun Liu, Xinghao Pan, Ying Xue, Meiqi Feng, Tianlei Ying, Pingyu Zhou, Zhanshuai Wu, Jian Xiao, Renfang Zhang, Jing Leng, Yongtao Sun, Xiaoyan Zhang, Jianqing Xu, 2024
Safety and clinical response to combined immunotherapy with autologous iNKT cells and PD-1+CD8+ T cells in patients failing first-line chemotherapy in stage IV pancreatic cancer, Wang J, Cheng X, Jin Y, Xia B, Qin R, Zhang W, Hu H, Mao X, Zhou L, Yan J, Zhang X, Xu J, 2023
Induced regulatory T cells modified by knocking down T-bet in combination with ectopic expression of inhibitory cytokines effectively protect Graft-versus-Host Disease, Rongrong Gao, Ang Li, Sen Li, Xiangrong Li, Shuye Zhang, Xiaoyan Zhang, Jianqing Xu, 2023
A single vaccination of nucleoside-modified Rabies mRNA vaccine induces prolonged highly protective immune responses in mice, Shimeng Bai, Tianhan Yang, Cuisong Zhu, Meiqi Feng, Li Zhang, Ziling Zhang, Xiang Wang, Rui Yu, Xinghao Pan, Chen Zhao, Jianqing Xu, Xiaoyan Zhang, 2023
Improving the ex vivo expansion of human tumor-reactive CD8 + T cells by targeting Toll-like receptors, Chenli Qiu, Jing Wang, Lingyan Zhu, Xiaobo Cheng, Bili Xia, Yanling Jin, Qin Ran, Linxia Zhang, Huiliang Hu, Jia Yan, Chen Zhao, Xiaoyan Zhang, Jianqing Xu, 2022
Rapid generation of a mouse model for evaluating on-target normal tissue toxicity of human CAR-T cells using replication-defective recombinant adenovirus, Qibin Liao, Zhuoqun Liu, Cuisong Zhu, Huan He, Meiqi Feng, Lang Jiang, Xiangqing Ding, Rongxun Sun, Xiaoyan Zhang, Jianqing Xu, 2022
Pathologically complete remission to combination of invariant NK T cells and anti-CD20 antibody in a refractory HIV+ diffuse large B-cell lymphoma patient, Jing Wang, Renfang Zhang, Xiangqing Ding, Yanling Jin, Ran Qin, Bili Xia, Qibin Liao, Huiliang Hu, Wei Song, Zhenyan Wang, Xiaoyan Zhang, Jianqing Xu, 2022
Feasibility of iNKT cell and PD-1+CD8+ T cell-based immunotherapy in patients with lung adenocarcinoma: Preliminary results of a phase I/II clinical trial, Xiaobo Cheng, Jing Wang, Chenli Qiu, Yanling Jin, Bili Xia, Ran Qin, Huiliang Hu, Jia Yan, Xiaoyan Zhang, Jianqing Xu, 2022
Prompt Antiviral Action of Pulmonary CD8+ TRM Cells Is Mediated by Rapid IFN-γ Induction and Its Downstream ISGs in the Lung, Jiang Lang, Liu Lu, Zhang Miaomiao, Zhang Linxia, Zhu Cuisong, He Qian, Ye Lilin, Zhao Chen, Li Zejun, Xu Jianqing, Zhang Xiaoyan, 2022
Nonmuscle myosin heavy chain IIA facilitates SARS-CoV-2 infection in human pulmonary cells, Jian Chen, Jun Fan, Zhilu Chen, Miaomiao Zhang, Haoran Peng, Jian Liu, Longfei Ding, Mingbin Liu, Chen Zhao, Ping Zhao, Shuye Zhang, Xiaoyan Zhang, Jianqing Xu, 2021
Conditioned CAR-T cells by hypoxia-inducible transcription amplification (HiTA) system significantly enhances systemic safety and retains antitumor efficacy, Huan He, Qibin Liao, Chen Zhao, Cuisong Zhu, Meiqi Feng, Zhuoqun Liu, Lang Jiang, Linxia Zhang, Xiangqing Ding, Min Yuan, Xiaoyan Zhang, Jianqing Xu, 2021
IL-21 arming potentiates the anti-tumor activity of an oncolytic vaccinia virus in monotherapy and combination therapy, Tianyue Chen, Xiangqing Ding, Qibin Liao, Nan Gao, Ye Chen, Chen Zhao, Xiaoyan Zhang, Jianqing Xu, 2021
Early plasma IL-37 responses accompanied with low inflammatory cytokines correlate with benign clinical outcomes during SARS-CoV-2 infection, Ang Li, Yun Lin, Zhigang Song, Xiaobo Cheng, Weihui Fu, Yan Liu, Huiliang Hu, Songhua Yuan, Jian Chen, Jun Fan, Min Wang, Jing Wang, Yanling Jin, Miaomiao Zhang, Lingyan Zhu, Peng Sun, Linxia Zhang, Ran Qin, Wei Zhang, Chenli Qiu, Yinzhong Shen, Lin Zhang, Tongyu Zhu, Hongzhou Lu, Xiaoyan Zhang, Jianqing Xu, 2020
PD-L1 chimeric costimulatory receptor improves the efficacy of CAR-T cells for PD-L1-positive solid tumors and reduces toxicity in vivo, Qibin Liao, Yunyu Mao, Huan He, Xiangqing Ding, Xiaoyan Zhang, Jianqing Xu, 2020
Engineering T cells with hypoxia-inducible chimeric antigen receptor (HiCAR) for selective tumor killing, Qibin Liao, Huan He, Yunyu Mao, Xiangqing Ding, Xiaoyan Zhang, Jianqing Xu, 2020
A Systemic Prime-Intrarectal Pull Strategy Raises Rectum-Resident CD8+ T Cells for Effective Protection in a Murine Model of LM-OVA Infection, Qian He, Lang Jiang, Kangli Cao, Linxia Zhang, Xinci Xie, Shuye Zhang, Xiangqing Ding, Yongquan He, Miaomiao Zhang, Tianyi Qiu, Xuanxuan Jin, Chen Zhao, Xiaoyan Zhang, Jianqing Xu, 2020
An open-label, randomized trial of the combination of IFN-κ plus TFF2 with standard care in the treatment of patients with moderate COVID-19, Weihui Fu, Yan Liu, Li Liu, Huiliang Hu, Xiaobo Cheng, Ping Liu, Zhigang Song, Lijun Zha, Shimeng Bai, Tingting Xu, Songhua Yuan, Fengru Lu, Zhiying Shang, Yihong Zhao, Jing Wang, Jun Zhao, Longfei Ding, Jun Chen, Lin Zhang, Tongyu Zhu, Xiaoyan Zhang, Hongzhou Lu, Jianqing Xu, 2020
